rumor
    rumor
    • Screeners
    • Heatmaps
    • Charts
    • News
    • Documentation
    • Pricing
    • FAQ
    You're viewing limited data.
    Log inSign up

    Sign up

    24 hours of full access, free. No credit card.

    Log inPricing
    1 asset

    Market news

    TypeAll
    SortNewest
    Assets
    AGIO
    Type
    TypeAll
    All
    Sort
    SortNewest
    Newest

    Filter by asset

      Agios Pharmaceuticals (AGIO) Stock Looks Pricey Despite Its 39% Run
      Nov 7Yahoo FinanceAGIO
      Agios Pharmaceuticals Inc (AGIO) (Q3 2026) Earnings Call Highlights: Revenue Surges 4x on ...

      Agios Pharmaceuticals Inc (AGIO) posted record Q3 2026 revenue of $55.4 million, cut R&D headcount by over 35%, and is launch-ready for sickle cell ahead of a February 2027 PDUFA date.

      Nov 6Yahoo FinanceAGIO
      Agios Pharmaceuticals, Inc. Q3 2026 Earnings Call Summary
      Nov 5Yahoo FinanceAGIO
      Truist cuts Agios Pharma stock price target on SCD concerns
      Nov 5Investing.comAGIO
      What Agios Pharmaceuticals (AGIO) Said on Its Q3 Earnings Call
      Nov 5Yahoo FinanceAGIO
      Agios Pharmaceuticals Q3 2026 Earnings Call Transcript
      Nov 5BenzingaAGIO
      Agios Pharmaceuticals (AGIO) Reports Q3 Loss, Beats Revenue Estimates
      Nov 5Yahoo FinanceAGIO
      Agios Pharmaceuticals: Q3 Earnings Snapshot
      Nov 5Yahoo FinanceAGIO
      Analysts’ Opinions Are Mixed on These Healthcare Stocks: Agios Pharma (AGIO) and Summit Therapeutics (SMMT)

      Detailed price information for Agios Pharmaceuticals (AGIO-Q) from The Globe and Mail including charting and trades.

      Nov 5The Globe and MailAGIO
      Agios earnings ahead: Can thalassemia offset drug delay?
      Nov 4Investing.comAGIO
      Will FDA Review Delay Change Agios Stock Narrative

      Agios Pharmaceuticals reported that the FDA has extended the PDUFA goal date for its Priority Review sNDA for mitapivat in sickle cell disease to February 1, 2027, after the agency classified new safety data and REMS related information as a major amendment. The firm is leaning on extensive RISE UP and REIGNITE trial data and ongoing labeling talks to keep mitapivat’s sickle cell opportunity on track, despite a longer review clock and added regulatory work on potential REMS requirements. We...

      Nov 4Yahoo FinanceAGIO
      Agios: News On Sickle Cell Approval Decision Delay May Not Derail Bull Thesis (AGIO)

      Agios Pharmaceuticals stock fell >15% after the FDA extended the mitapivat sNDA PDUFA date for sickle cell disease to February 2027. I rate AGIO stock as Buy. Read my update.

      Oct 30Seeking AlphaAGIO
      Agios stock falls on FDA review extension (AGIO:NASDAQ)

      Agios Pharmaceuticals (AGIO) stock fell after the FDA delayed the review of the firm's application for a label expansion of its lead product, Pyrukynd. Read more here.

      Oct 30Seeking AlphaAGIO
      Agios Pharmaceuticals (AGIO) Expected to Beat Earnings Estimates: What to Know Ahead of Q3 Release
      Oct 29Yahoo FinanceAGIO
      Did Priority Review Just Shift Agios Pharmaceuticals' (AGIO) Investment Narrative?

      Agios Pharmaceuticals is pursuing US FDA accelerated approval for mitapivat in sickle cell disease after Priority Review of Phase 3 RISE UP data showing significant hemoglobin responses in patients aged 16 and older. The mixed RISE UP outcome, with strong hemoglobin results but no statistically significant reduction in pain crises, highlights both the clinical opportunity and the trial design risk Agios must manage as it builds a rare disease franchise around mitapivat. We will examine how...

      Oct 20Yahoo FinanceAGIO
      FDA Decision Watch: What Investors Need To Know About Four Upcoming Drug Rulings
      Oct 19Yahoo FinanceAGIOINO
      Cantor Fitzgerald reiterates Agios Pharma stock rating ahead of PDUFA
      Oct 15Investing.comAGIO
      Agios Pharmaceuticals (AGIO) Could Be 28% Undervalued Following Its November Results Call Date
      Oct 10Yahoo FinanceAGIO
      Agios Pharma (AGIO) Gets a Hold from RBC Capital

      Detailed price information for Agios Pharmaceuticals (AGIO-Q) from The Globe and Mail including charting and trades.

      Oct 10The Globe and MailAGIO
      Agios Pharmaceuticals (AGIO) Stock Looks Fully Priced Against Current Sales
      Oct 9Yahoo FinanceAGIO
      Agios' Growth Story Hinges on Mitapivat's Commercial Expansion
      Oct 2Yahoo FinanceAGIO

      This is the newest page. Registered accounts read further back.